Treatment effect and safety profile of salvage chemotherapy following immune checkpoint inhibitors in lung cancer

AIM: To assess the relationship of treatment effects between immune checkpoint inhibitor (ICI) and salvage chemotherapy, with the safety profile of salvage chemotherapy. PATIENTS & METHODS: 18 patients with advanced NSCLC treated using salvage chemotherapy following ICI treatment were retrospect...

Descripción completa

Detalles Bibliográficos
Autores principales: Tone, Mari, Izumo, Takehiro, Awano, Nobuyasu, Kuse, Naoyuki, Inomata, Minoru, Jo, Tatsunori, Yoshimura, Hanako, Miyamoto, Shingo, Kunitoh, Hideo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Future Medicine Ltd 2019
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6802711/
https://www.ncbi.nlm.nih.gov/pubmed/31645892
http://dx.doi.org/10.2217/lmt-2019-0001
_version_ 1783460845500497920
author Tone, Mari
Izumo, Takehiro
Awano, Nobuyasu
Kuse, Naoyuki
Inomata, Minoru
Jo, Tatsunori
Yoshimura, Hanako
Miyamoto, Shingo
Kunitoh, Hideo
author_facet Tone, Mari
Izumo, Takehiro
Awano, Nobuyasu
Kuse, Naoyuki
Inomata, Minoru
Jo, Tatsunori
Yoshimura, Hanako
Miyamoto, Shingo
Kunitoh, Hideo
author_sort Tone, Mari
collection PubMed
description AIM: To assess the relationship of treatment effects between immune checkpoint inhibitor (ICI) and salvage chemotherapy, with the safety profile of salvage chemotherapy. PATIENTS & METHODS: 18 patients with advanced NSCLC treated using salvage chemotherapy following ICI treatment were retrospectively included. We assessed the overall response rate to and adverse events of salvage chemotherapy. RESULTS: The overall response rate to salvage chemotherapy was 33.3% and that of ICI responders was significantly higher than that of ICI nonresponders (66.7 vs 16.7%, respectively, p = 0.03). The incidence rate of adverse events to salvage chemotherapy was 55.6%. CONCLUSION: The efficacy of salvage chemotherapy was similar to that preceding ICI. Moreover, the safety of salvage chemotherapy was good.
format Online
Article
Text
id pubmed-6802711
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Future Medicine Ltd
record_format MEDLINE/PubMed
spelling pubmed-68027112019-10-23 Treatment effect and safety profile of salvage chemotherapy following immune checkpoint inhibitors in lung cancer Tone, Mari Izumo, Takehiro Awano, Nobuyasu Kuse, Naoyuki Inomata, Minoru Jo, Tatsunori Yoshimura, Hanako Miyamoto, Shingo Kunitoh, Hideo Lung Cancer Manag Research Article AIM: To assess the relationship of treatment effects between immune checkpoint inhibitor (ICI) and salvage chemotherapy, with the safety profile of salvage chemotherapy. PATIENTS & METHODS: 18 patients with advanced NSCLC treated using salvage chemotherapy following ICI treatment were retrospectively included. We assessed the overall response rate to and adverse events of salvage chemotherapy. RESULTS: The overall response rate to salvage chemotherapy was 33.3% and that of ICI responders was significantly higher than that of ICI nonresponders (66.7 vs 16.7%, respectively, p = 0.03). The incidence rate of adverse events to salvage chemotherapy was 55.6%. CONCLUSION: The efficacy of salvage chemotherapy was similar to that preceding ICI. Moreover, the safety of salvage chemotherapy was good. Future Medicine Ltd 2019-05-09 /pmc/articles/PMC6802711/ /pubmed/31645892 http://dx.doi.org/10.2217/lmt-2019-0001 Text en © 2019 Takehiro Izumo This work is licensed under the Attribution-NonCommercial-NoDerivatives 4.0 Unported License (http://creativecommons.org/licenses/by-nc-nd/4.0/)
spellingShingle Research Article
Tone, Mari
Izumo, Takehiro
Awano, Nobuyasu
Kuse, Naoyuki
Inomata, Minoru
Jo, Tatsunori
Yoshimura, Hanako
Miyamoto, Shingo
Kunitoh, Hideo
Treatment effect and safety profile of salvage chemotherapy following immune checkpoint inhibitors in lung cancer
title Treatment effect and safety profile of salvage chemotherapy following immune checkpoint inhibitors in lung cancer
title_full Treatment effect and safety profile of salvage chemotherapy following immune checkpoint inhibitors in lung cancer
title_fullStr Treatment effect and safety profile of salvage chemotherapy following immune checkpoint inhibitors in lung cancer
title_full_unstemmed Treatment effect and safety profile of salvage chemotherapy following immune checkpoint inhibitors in lung cancer
title_short Treatment effect and safety profile of salvage chemotherapy following immune checkpoint inhibitors in lung cancer
title_sort treatment effect and safety profile of salvage chemotherapy following immune checkpoint inhibitors in lung cancer
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6802711/
https://www.ncbi.nlm.nih.gov/pubmed/31645892
http://dx.doi.org/10.2217/lmt-2019-0001
work_keys_str_mv AT tonemari treatmenteffectandsafetyprofileofsalvagechemotherapyfollowingimmunecheckpointinhibitorsinlungcancer
AT izumotakehiro treatmenteffectandsafetyprofileofsalvagechemotherapyfollowingimmunecheckpointinhibitorsinlungcancer
AT awanonobuyasu treatmenteffectandsafetyprofileofsalvagechemotherapyfollowingimmunecheckpointinhibitorsinlungcancer
AT kusenaoyuki treatmenteffectandsafetyprofileofsalvagechemotherapyfollowingimmunecheckpointinhibitorsinlungcancer
AT inomataminoru treatmenteffectandsafetyprofileofsalvagechemotherapyfollowingimmunecheckpointinhibitorsinlungcancer
AT jotatsunori treatmenteffectandsafetyprofileofsalvagechemotherapyfollowingimmunecheckpointinhibitorsinlungcancer
AT yoshimurahanako treatmenteffectandsafetyprofileofsalvagechemotherapyfollowingimmunecheckpointinhibitorsinlungcancer
AT miyamotoshingo treatmenteffectandsafetyprofileofsalvagechemotherapyfollowingimmunecheckpointinhibitorsinlungcancer
AT kunitohhideo treatmenteffectandsafetyprofileofsalvagechemotherapyfollowingimmunecheckpointinhibitorsinlungcancer

Ejemplares similares